Tumor necrosis factor-α production-enhancing properties of novel adamantylalkylthio derivatives of some heterocyclic compounds

Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences

Volumn 60, Issue 4, 2005, Pages 471-475

  Orzeszko, Barbara ^a   Świtaj, Tomasz ^b   Jakubowska Mućka, Anna B ^b   Lasek, Witold ^b   Orzeszko, Andrzej ^c,d   Kazimierczuk, Zygmunt ^c,e  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d MILITARY UNIVERSITY OF TECHNOLOGY   (Poland)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Adamantylated Pyridines; Adamantylated Pyrimidines; Cytotoxicity; TNF

Indexed keywords

CELL CULTURE; CELL DEATH; CYTOTOXICITY; GLYCOPROTEINS; MACROPHAGES; TUMORS;

ADAMANTYLATED PYRIMIDINES; CELL LINES; CYTOKINES; HETEROCYCLES; HETEROCYCLIC COMPOUND; MELANOMA CELLS; TUMOR NECROSIS FACTOR ALPHA;

AROMATIC COMPOUNDS;

2 (1 ADAMANTYLAMINO) 6 METHYLPYRIDINE; 2 (2 ADAMANTAN 1 YL ETHYLSULFANYL) 1 METHYL 1H IMIDAZOLE; 2 (2 ADAMANTAN 1 YLETHYLSULFANYL) 4 METHYLPYRIMIDINE; 2 (2 ADAMANTAN 1 YLETHYLSULFANYL) 4,5 DIHYDROTHIAZOLE; 2 (2 ADAMANTAN 1 YLETHYLSULFANYL) 6 METHYLPYRIDINE; 2 (2 ADAMANTAN 1 YLETHYLSULFANYL)PYRIDINE; 2 (2 ADAMANTAN 1 YLETHYLSULFANYL)PYRIMIDINE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL) 1 METHYL 1H IMIDAZOLE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL) 4 METHYLPYRIMIDINE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL) 4,5 DIHYDROTHIAZOLE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL) 4,6 DIMETHYLPYRIMIDINE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL) 6 METHYLPYRIDINE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL)PYRIDINE; 2 (ADAMANTAN 1 YLMETHYLSULFANYL)PYRIMIDINE; ADAMANTANE DERIVATIVE; HETEROCYCLIC COMPOUND; PICOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ARTICLE; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; MASS SPECTROMETRY; MELANOMA CELL; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 19444368210     PISSN: 09320776     EISSN: None     Source Type: Journal    
DOI: 10.1515/znb-2005-0419     Document Type: Article

References (20)

1. E.A. CarswelL L.J. Old, R.L. Kassel, N. Foire, B. Williamson, Proc. Natl. Acad. Sci. USA 72, 3666 (1975).
2. D. Manney, C. Murray, W. Risau, M. Clauss, Immunol. Today 17, 254 (1996).
3. Y. Hashimoto, Curr. Med. Chem. 5, 163 (1998)
4. Y. Shibata, K. Sasaki, Y. Hashimoto, S. Iwasaki, Biochem. Biophys. Res. Commun. 205, 1992 (1994).
5. M. Fujita, T. Hirayama, N. Ikeda, Bioorg. Med. Chem. 10, 3113 (2002).
6. M. Feldmann, Nature Rev. Immunol. 2, 364 (2002).
7. F.J. Lejeune, C. Ruegg, D. Lienard, Curr. Opin. Immunol. 10, 573 (1998)
8. K. Pfeffer, Cytokine Growth Factor Rev. 14, 185 (2003).
9. Y. Shibata, M. Shichita, K. Sasaki, K. Nishimura, Y. Hashimoto, S. Iwasaki, Chem. Pharm. Bull. 43, 177 (1995).
10. Z. Kazimierczuk, A. Górska, T. Świtaj, W. Lasek, Bioorg. Med. Chem. Lett. 11, 1197 (2001).
11. J.K. Maurin, W. Lasek, A. Górska, T. Świtaj, M. Wamil, I. Młynarczuk, Z. Kazimierczuk, Anticancer Drug Des. 16, 73 (2001).
12. A. Orzeszko, W. Lasek, T. Świtaj, M. Stoksik, B. Kamińska, Farmaco 58, 371 (2003).
13. A. Górska, T. Świtaj, I. Młynarczuk, W. Lasek, Z. Kazimierczuk, Acta Polon. Pharm. - Drug Res. 59, 415 (2002).
14. J.K. Maurin, W. Lasek, A. Górska, T. Świtaj, A.B. Jakubowska, Z. Kazimierczuk, Chem. Biodiv. 1, 1488 (2004).
15. W. Lasek, A. Mackiewicz, A. Czajka, T. Świtaj, J. Gołab, M. Wiznerowicz, G. Korczak-Kowalska, E. Z. Balkowiec-Iskra, K. Gryska, D. Izycki, M. Jakóbisiak, Cancer Gene Ther. 7, 1581 (2000).
16. P. Rizza, M. Ferrantini, I. Capone, F. Belardelli, Trends Immunol. 23, 381 (2002).
17. A.L. Rachmilevich, K. Janssen, Z. Hao, P.M. Sondel, N.S. Yang, Cancer Gene Ther. 7, 826 (2000).
18. E. Di Carlo, A. Comes, S. Basso, A. De Ambrosis, R. Maezza, P. Musiani, K. Moelling, A. Albini, S. Ferrini, J. Immunol. 165, 3111 (2000).
19. G. Parmiani, M. Rodolfo, C. Melani. Human Gene Ther. 11, 1269 (2000).
20. M. Bochmann, G. Wilkinson, B.G. Brent, J. Chem. Soc. Dalton Trans. 1879 (1980).